# Aditya Bardia

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/aditya-bardia/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,117 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 90 |
| i10-index | 323 |
| Last Known Institution | University of California, Los Angeles |
| OpenAlex ID | https://openalex.org/A5034972183 |
| ORCID iD | https://orcid.org/0000-0003-4885-1157 |
| Works | 1,143 |

## Researcher papers

- [Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition](https://scholariq.org/papers/circulating-breast-tumor-cells-exhibit-dynamic-changes-in-epithelial-and/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-hziy-in-refractory-metastatic-triple-negative-breast/)
- [Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial](https://scholariq.org/papers/elacestrant-oral-selective-estrogen-receptor-degrader-versus-standard-endocrine/)
- [Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis](https://scholariq.org/papers/malignant-melanoma-in-the-21st-century-part-1-epidemiology-risk-factors/)
- [Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis](https://scholariq.org/papers/malignant-melanoma-in-the-21st-century-part-1-epidemiology-risk-factors-2/)
- [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://scholariq.org/papers/biomarker-analyses-in-the-phase-iii-ascent-study-of-sacituzumab-govitecan-versus/)
- [PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer](https://scholariq.org/papers/pten-loss-mediates-clinical-cross-resistance-to-cdk4-6-and-pi3k-inhibitors-in/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

## Researcher university

- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.